Replacement of EVOS imaging systemview on SAM.gov

General Information Document Type: Presolicitation Synopsis Number: 75N98026Q00793 Posted Date: July 15, 2026 Original Response Date: July 27, 2026 Current Response Date: July 27, 2026 Set Aside: N/A NAICS Code: 334516 Contracting Office Address National Institutes of Health (NIH), Office of the Director (OD) Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM) Hospital and Laboratory Support Division 6701 Rockledge Drive Bethesda, MD 20817 Description INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: Life Technologies Corporation 5781 Van Allen Way Carlsbad, CA 92008 NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 334516 with a Size Standard $1000. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: Replacement of EVOS imaging system Background Information: The EVOS imaging system is a critical instrument supporting research conducted by the Mili lab as well as additional groups within the Laboratory of Cellular and Molecular Biology (LCMB), NIH/NCI. The system has served as a workhorse instrument for visualizing live and fixed cell populations—a fundamental requirement for experimental studies of cancer cells expressing fluorescently-labeled pro-teins or treated with fluorescent compounds. Routine monitoring of these cell lines requires a dedicated microscope system for daily assessment of cell growth and maintenance of optimal culture conditions. Furthermore, prior to initiating costly and time-intensive experimental protocols, expression patterns and levels of fluorescent constructs must be evaluated to ensure the acquisition of high-quality, repro-ducible data. The system additionally provides critical imaging capabilities, including high-quality sin-gle time-point and time-lapse acquisitions across multiple fluorescence channels. It thus serves as a valuable alternative for applic…